Faropenem: Difference between revisions
m Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +) |
Rabin Bista (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{drugbox | | {{drugbox | | ||
| IUPAC_name = (5''R'',6''R'')-6-(1-hydroxyethyl)-7-oxo-3-[(2''R'')-<br>oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]<br>hept-2-ene-2-carboxylic acid | | IUPAC_name = (5''R'',6''R'')-6-(1-hydroxyethyl)-7-oxo-3-[(2''R'')-<br>oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]<br>hept-2-ene-2-carboxylic acid | ||
| image = Faropenem. | | image = Faropenem Wiki Str.png | ||
| CAS_number = 106560-14-9 | | CAS_number = 106560-14-9 | ||
| ATC_prefix = | | ATC_prefix = | ||
| Line 24: | Line 24: | ||
| routes_of_administration = Oral | | routes_of_administration = Oral | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
== Overview == | |||
'''Faropenem''' is an orally-active [[beta-lactam antibiotic]] belonging to the [[penem]] group. It is the first orally-active penem antibiotic. Faropenem was developed by [[Daiichi Asubio Pharma]], which markets it in two forms. | '''Faropenem''' is an orally-active [[beta-lactam antibiotic]] belonging to the [[penem]] group. It is the first orally-active penem antibiotic. Faropenem was developed by [[Daiichi Asubio Pharma]], which markets it in two forms. | ||
* The sodium salt '''faropenem sodium''', available under the trade name '''Farom''', has been marketed in Japan since [[1997]]. ({{PubChem|636379}}) | * The sodium salt '''faropenem sodium''', available under the trade name '''Farom''', has been marketed in Japan since [[1997]]. ({{PubChem|636379}}) | ||
| Line 44: | Line 45: | ||
* [http://www.asubio.co.jp/eg/productinfo/index.html Daiichi Asubio Pharma products page] | * [http://www.asubio.co.jp/eg/productinfo/index.html Daiichi Asubio Pharma products page] | ||
[[Category:Drug]] | |||
[[Category:Carbapenem antibiotics]] | [[Category:Carbapenem antibiotics]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 14:25, 13 April 2015
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H15NO5S |
| Molar mass | 285.317 g/mol |
|
WikiDoc Resources for Faropenem |
|
Articles |
|---|
|
Most recent articles on Faropenem |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Faropenem at Clinical Trials.gov Clinical Trials on Faropenem at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Faropenem
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Faropenem Discussion groups on Faropenem Directions to Hospitals Treating Faropenem Risk calculators and risk factors for Faropenem
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Faropenem |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Faropenem is an orally-active beta-lactam antibiotic belonging to the penem group. It is the first orally-active penem antibiotic. Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms.
- The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (Template:PubChem)
- The prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem but company officials recently announced that this name was rejected by the FDA. (Q1 06 Investor Conf Call)(Template:PubChem)
The company also stated their hope to have the product available for commercial sale months before the 2007 influenza season.
Clinical use
Faropenem has yet to receive marketing approval in the United States, and was submitted for consideration by the United States Food and Drug Administration (FDA) on 20 December 2005. The new drug application (NDA) dossier submitted included four proposed indications:
- acute bacterial sinusitis
- community acquired pneumonia
- acute exacerbations of chronic bronchitis
- uncomplicated skin and skin structure infections
External links
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drug
- Carbapenem antibiotics